New Product: Kaftrio (ivacaftor, tezacaftor, elexacaftor) tablets

Kaftrio is licensed for the treatment of cystic fibrosis (CF) in patients from 12yrs who are homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene or heterozygous for F508del in the CFTR gene with a minimal function (MF) mutation.


electronic Medicines compendium